IHI vs RSPH

Key Takeaways

• IHI offers targeted exposure to U.S. medical device manufacturers via a market-cap-weighted index, with top 10 holdings comprising over 75% of assets, leading to higher concentration risk compared to RSPH's equal-weight approach.
• RSPH provides broader healthcare sector diversification across approximately 59 S&P 500 health care stocks, equally weighted, reducing single-stock risk but including providers and pharma alongside devices.
• Both ETFs carry similar expense ratios around 0.40%, with IHI at 0.38% and RSPH at 0.40%, making cost a neutral factor in comparison.
• IHI exhibits higher volatility due to its niche focus on growth-oriented medical devices, while RSPH's broader mandate offers more stability through equal weighting and inclusion of defensive healthcare subsectors.
• In recent market cycles, RSPH has shown relative resilience amid healthcare sector pressures, benefiting from diversification, whereas IHI has faced sharper drawdowns tied to device-specific headwinds.
• Thematic positioning favors IHI for pure-play innovation in medical technology, while RSPH suits investors seeking comprehensive healthcare exposure with lower concentration.

Introduction

Comparing IHI and RSPH highlights key trade-offs in healthcare ETF investing. Both provide exposure to the resilient healthcare sector but differ structurally: IHI targets the high-growth medical devices subsector, while RSPH delivers equal-weighted access to the broader S&P 500 healthcare universe. This comparison is timely amid ongoing sector rotation toward defensive areas, aging demographics boosting demand for devices and services, and macroeconomic shifts like interest rate dynamics influencing growth stocks. Investors weighing concentrated innovation plays against diversified stability will find these ETFs represent alternative paths to healthcare sector exposure.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI) is a passive fund tracking the Dow Jones U.S. Select Medical Equipment Index, focusing on U.S. companies manufacturing and distributing non-disposable medical devices like MRI scanners, pacemakers, prosthetics, and surgical tools. It holds approximately 47 stocks in a market-cap-weighted manner, resulting in high concentration: the top 10 holdings represent about 75% of assets. Key positions include ISRG (Intuitive Surgical, 16.53%), ABT (Abbott Laboratories, 16.06%), and SYK (Stryker, 11.04%). Sector allocation is 100% healthcare, specifically health technology/medical equipment. The expense ratio is 0.38%, with quarterly distributions. As a non-diversified thematic ETF, IHI emphasizes innovation-driven growth but carries elevated volatility from its narrow focus.

Invesco S&P 500® Equal Weight Health Care ETF (RSPH) Overview

The Invesco S&P 500® Equal Weight Health Care ETF (RSPH) passively tracks the S&P 500 Equal Weight Health Care Index, comprising all healthcare constituents from the S&P 500 (about 59 holdings), equally weighted to mitigate mega-cap dominance. Top 10 holdings, each around 2%, include CNC (Centene, 2.65%), HUM (Humana, 2.45%), and UNH (UnitedHealth, 2.30%), spanning providers, pharma, and devices. Sector allocation is 100% healthcare, with roughly 68% health technology, 22% health services, and smaller biotech/distribution exposures. The expense ratio stands at 0.40%, with quarterly rebalancing to maintain equal weights. This structure promotes broader diversification across healthcare subsectors, enhancing stability relative to cap-weighted peers.

Industry and Thematic Backdrop

The healthcare sector benefits from structural tailwinds like aging populations and rising chronic disease prevalence, driving demand for medical devices and services. Catalysts include AI integration in diagnostics/robotics, M&A resurgence in biotech/pharma, and longevity tech innovations. Capital flows have favored defensive healthcare amid economic uncertainty, though medical devices face near-term risks from hospital spending caution, procedural delays, and reimbursement pressures. Regulatory shifts, such as potential drug pricing reforms, add complexity, while macroeconomic factors like interest rates impact growth-oriented device firms more than diversified providers. Both ETFs navigate this environment, with devices poised for long-term expansion via technological breakthroughs but exposed to cyclical volatility.

Performance and Positioning Comparison

In recent months, RSPH has demonstrated greater relative stability, with shallower drawdowns during healthcare pullbacks, thanks to its equal-weight diversification across providers and pharma buffering device weakness. IHI, conversely, has experienced heightened volatility, reflecting concentration in growth stocks sensitive to earnings cycles and rate expectations. Over broader recent market cycles, RSPH's balanced exposure has supported steadier returns amid sector rotation toward value/defensives, while IHI's positioning amplifies upside from device innovation but heightens downside risks tied to procedural volumes and medtech sentiment. Volatility metrics underscore IHI's higher beta profile versus RSPH's moderated swings.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes. Explore it today to uncover hidden gems in sectors like healthcare.

Tickeron AI Verdict

Tickeron’s AI currently favors RSPH with moderate conviction (60-70% probability edge). Its superior diversification, lower concentration risk, and relative trend consistency in recent cycles outweigh IHI’s thematic growth potential amid elevated device sector volatility and softer procedural demand. RSPH’s equal-weight structure enhances resilience across healthcare subsectors, aligning better with current momentum toward balanced exposure, though IHI could regain favor if medtech innovation accelerates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations